WHY R&D PRODUCTIVITY IS FALLING, AND WHAT CAN BE DONE
Exh 1: Real economic returns to R&D spending (chart)
Exh 2: Innovative yield per $1M real R&D spend (3yr MA) (chart)
Exh 3: Innovation yield is falling because of rising input costs, not because of falling quality – if anything quality is improving (chart)
Exh 4: Average per-patient trial costs (table)
Exh 5: Clinical trial protocol complexity and administrative burden (table)
Exh 6: Likelihood of product approval by author, era, and basis (self-originated compounds only, v. all compounds) (chart)
Exh 7: Phase-specific approval probabilities, by era (chart)
Exh 8: Avg rank (share of quality-adjusted innovation) in research areas that account for 80 percent of each company’s phase 2 and earlier innovation (table)
Exh 9: Internal bias index (table)
Exh 10: Share of risk-adjusted approvals for active development projects, by ICD-9 (table)
Exh 11: Average time to failure versus typical portfolio return on R&D spending (chart)
Exh 12: Economic returns v. R&D spend by company, 1993-2014 (chart)
Exh 13: Quality of innovation v. R&D spend by company, 1993-2014 (chart)
Exh 14: Annual R&D spend v. average relative quality of innovation: Amgen (chart)
Exh 15: Annual R&D spend v. average relative quality of innovation: Biogen (chart)
Exh 16: Annual R&D spend v. average relative quality of innovation: Gilead (chart)
Exh 17: Annual R&D spend v. average relative quality of innovation: Vertex (chart)
Exh 18: Typical portfolio returns on R&D spending as a function of average real net price inflation in US (chart)
Exh 19: Peer group coverage ratios and projected growth, 2014-2021E (table)
Exh 20: Probability of achieving 3 launches per year by clinical development portfolio size (by phase) (chart)
Exh 21: Hypothetical portfolio sizing model (chart)
THE METRICS
Exh 22: Share of trailing 10-y R&D spend v. Share of risk-adjusted new product launches, 2016-2023 (chart)
Exh 23: AbbVie potential/risk-adjusted launches, 2016-2021E (chart)
Exh 24: AbbVie Expected in-line and pipline pharma sales ($M), 2014-2021E (chart)
Exh 25: Real annual economic returns to R&D spending (chart)
Exh 26: Projected real economic returns to R&D spending (chart)
Exh 27: Typical economic returns to R&D spending as a function of average real net price inflation in US (chart)
Exh 28: Innovation yield per $1M real R&D spend (3yr MA) (chart)
Exh 29: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh 30: Average relative quality of innovation (3yr MA): Novo Nordisk v. Alexion (chart)
Exh 31: BMY development by ICD-9 v. peer group (table)
Exh 32: Bristol-Myers Squibb development by mechanism v. peer group (table)
Exh 33: Share of Bristol-Myers Squibb risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh 34: Bristol-Myers Squibb development leadership in targeted MOA/ICD-9 pairs (table)
Exh 35: Roche ‘Hidden Pipeline’ by therapeutic category v. peer group (table)
Exh 36: Internal bias index = company’s share of development spending on internal discoveries / company’s share of global biomedical innovation (chart)
THE RANKINGS
Exh 37a: Summary peer group performance and rankings (table)
Exh 37b: Leadership & concentration of effort detail (table)
THE COMPANIES
AbbVie
Exh ABBV1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh ABBV2: AbbVie potential / risk-adjusted launches, 2016-2021E (chart)
Exh ABBV3: AbbVie Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh ABBV4: Projected real economic returns to R&D spending v. peer group (chart)
Exh ABBV5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh ABBV6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh ABBV7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh ABBV8: Development stage portfolio by ICD-9 v. peer group (table)
Exh ABBV9: Development stage portfolio by mechanism v. peer group (table)
Exh ABBV10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh ABBV11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh ABBV12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh ABBV13: Clinical development projects by source of innovations (table)
Alexion
Exh ALXN1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh ALXN2: Alexion potential / risk-adjusted launches, 2016-2021E (chart)
Exh ALXN3: Alexion Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh ALXN4: Projected real economic returns to R&D spending v. peer group (chart)
Exh ALXN5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh ALXN6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh ALXN7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh ALXN8: Development stage portfolio by ICD-9 v. peer group (table)
Exh ALXN9: Development stage portfolio by mechanism v. peer group (table)
Exh ALXN10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh ALXN11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh ALXN12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh ALXN13: Clinical development projects by source of innovations (table)
Amgen
Exh AMGN1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh AMGN2: Amgen potential / risk-adjusted launches, 2016-2021E (chart)
Exh AMGN3: Amgen Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh AMGN4: Projected real economic returns to R&D spending v. peer group (chart)
Exh AMGN5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh AMGN6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh AMGN7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh AMGN8: Development stage portfolio by ICD-9 v. peer group (table)
Exh AMGN9: Development stage portfolio by mechanism v. peer group (table)
Exh AMGN10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh AMGN11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh AMGN12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh AMGN13: Clinical development projects by source of innovations (table)
AstraZeneca
Exh AZN1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh AZN2: AstraZeneca potential / risk-adjusted launches, 2016-2021E (chart)
Exh AZN3: AstraZeneca Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh AZN4: Projected real economic returns to R&D spending v. peer group (chart)
Exh AZN5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh AZN6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh AZN7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh AZN8: Development stage portfolio by ICD-9 v. peer group (table)
Exh AZN9: Development stage portfolio by mechanism v. peer group (table)
Exh AZN10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh AZN11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh AZN12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh AZN13: Clinical development projects by source of innovations (table)
Bayer
Exh BAYER1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh BAYER2: Bayer potential / risk-adjusted launches, 2016-2021E (chart)
Exh BAYER3: Bayer Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh BAYER4: Projected real economic returns to R&D spending v. peer group (chart)
Exh BAYER5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh BAYER6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh BAYER7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh BAYER8: Development stage portfolio by ICD-9 v. peer group (table)
Exh BAYER9: Development stage portfolio by mechanism v. peer group (table)
Exh BAYER10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh BAYER11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh BAYER12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh BAYER13: Clinical development projects by source of innovations (table)
Biogen
Exh BIIB1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh BIIB2: Biogen potential / risk-adjusted launches, 2016-2021E (chart)
Exh BIIB3: Biogen Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh BIIB4: Projected real economic returns to R&D spending v. peer group (chart)
Exh BIIB5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh BIIB6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh BIIB7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh BIIB8: Development stage portfolio by ICD-9 v. peer group (table)
Exh BIIB9: Development stage portfolio by mechanism v. peer group (table)
Exh BIIB10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh BIIB11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh BIIB12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh BIIB13: Clinical development projects by source of innovations (table)
Bristol-Myers Squibb
Exh BMY1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh BMY2: Bristol-Myers Squibb potential / risk-adjusted launches, 2016-2021E (chart)
Exh BMY3: Bristol-Myers Squibb Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh BMY4: Projected real economic returns to R&D spending v. peer group (chart)
Exh BMY5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh BMY6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh BMY7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh BMY8: Development stage portfolio by ICD-9 v. peer group (table)
Exh BMY9: Development stage portfolio by mechanism v. peer group (table)
Exh BMY10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh BMY11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh BMY12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh BMY13: Clinical development projects by source of innovations (table)
Celgene
Exh CELG1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh CELG2: Celgene potential / risk-adjusted launches, 2016-2021E (chart)
Exh CELG3: Celgene Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh CELG4: Projected real economic returns to R&D spending v. peer group (chart)
Exh CELG5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh CELG6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh CELG7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh CELG8: Development stage portfolio by ICD-9 v. peer group (table)
Exh CELG9: Development stage portfolio by mechanism v. peer group (table)
Exh CELG10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh CELG11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh CELG12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh CELG13: Clinical development projects by source of innovations (table)
Gilead
Exh GILD1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh GILD2: Gilead potential / risk-adjusted launches, 2016-2021E (chart)
Exh GILD3: Gilead Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh GILD4: Projected real economic returns to R&D spending v. peer group (chart)
Exh GILD5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh GILD6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh GILD7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh GILD8: Development stage portfolio by ICD-9 v. peer group (table)
Exh GILD9: Development stage portfolio by mechanism v. peer group (table)
Exh GILD10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh GILD11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh GILD12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh GILD13: Clinical development projects by source of innovations (table)
GlaxoSmithKline
Exh GSK1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh GSK2: GlaxoSmithKline potential / risk-adjusted launches, 2016-2021E (chart)
Exh GSK3: GlaxoSmithKline Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh GSK4: Projected real economic returns to R&D spending v. peer group (chart)
Exh GSK5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh GSK6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh GSK7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh GSK8: Development stage portfolio by ICD-9 v. peer group (table)
Exh GSK9: Development stage portfolio by mechanism v. peer group (table)
Exh GSK10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh GSK11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh GSK12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh GSK13: Clinical development projects by source of innovations (table)
Johnson & Johnson
Exh JNJ1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh JNJ2: Johnson & Johnson potential / risk-adjusted launches, 2016-2021E (chart)
Exh JNJ3: Johnson & Johnson Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh JNJ4: Projected real economic returns to R&D spending v. peer group (chart)
Exh JNJ5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh JNJ6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh JNJ7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh JNJ8: Development stage portfolio by ICD-9 v. peer group (table)
Exh JNJ9: Development stage portfolio by mechanism v. peer group (table)
Exh JNJ10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh JNJ11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh JNJ12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh JNJ13: Clinical development projects by source of innovations (table)
Eli Lilly
Exh LLY1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh LLY2: Eli Lilly potential / risk-adjusted launches, 2016-2021E (chart)
Exh LLY3: Eli Lilly Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh LLY4: Projected real economic returns to R&D spending v. peer group (chart)
Exh LLY5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh LLY6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh LLY7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh LLY8: Development stage portfolio by ICD-9 v. peer group (table)
Exh LLY9: Development stage portfolio by mechanism v. peer group (table)
Exh LLY10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh LLY11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh LLY12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh LLY13: Clinical development projects by source of innovations (table)
Merck KgAA
Exh MKGAY1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh MKGAY2: Merck KgAA potential / risk-adjusted launches, 2016-2021E (chart)
Exh MKGAY3: Merck KgAA Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh MKGAY4: Projected real economic returns to R&D spending v. peer group (chart)
Exh MKGAY5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh MKGAY6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh MKGAY7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh MKGAY8: Development stage portfolio by ICD9 v. peer group (table)
Exh MKGAY9: Development stage portfolio by mechanism v. peer group (table)
Exh MKGAY10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh MKGAY11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh MKGAY12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh MKGAY13: Clinical development projects by source of innovations (table)
Merck
Exh MRK1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh MRK2: Merck potential / risk-adjusted launches, 2016-2021E (chart)
Exh MRK3: Merck Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh MRK4: Projected real economic returns to R&D spending v. peer group (chart)
Exh MRK5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh MRK6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh MRK7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh MRK8: Development stage portfolio by ICD-9 v. peer group (table)
Exh MRK9: Development stage portfolio by mechanism v. peer group (table)
Exh MRK10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh MRK11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh MRK12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh MRK13: Clinical development projects by source of innovations (table)
Novo Nordisk
Exh NVO1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh NVO2: Novo Nordisk potential / risk-adjusted launches, 2016-2021E (chart)
Exh NVO3: Novo Nordisk Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh NVO4: Projected real economic returns to R&D spending v. peer group (chart)
Exh NVO5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh NVO6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh NVO7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh NVO8: Development stage portfolio by ICD-9 v. peer group (table)
Exh NVO9: Development stage portfolio by mechanism v. peer group (table)
Exh NVO10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh NVO11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh NVO12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh NVO13: Clinical development projects by source of innovations (table)
Novartis
Exh NVS1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh NVS2: Novartis potential / risk-adjusted launches, 2016-2021E (chart)
Exh NVS3: Novartis Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh NVS4: Projected real economic returns to R&D spending v. peer group (chart)
Exh NVS5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh NVS6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh NVS7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh NVS8: Development stage portfolio by ICD-9 v. peer group (table)
Exh NVS9: Development stage portfolio by mechanism v. peer group (table)
Exh NVS10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh NVS11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh NVS12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh NVS13: Clinical development projects by source of innovations (table)
Pfizer
Exh PFE1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh PFE2: Pfizer potential / risk-adjusted launches, 2016-2021E (chart)
Exh PFE3: Pfizer Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh PFE4: Projected real economic returns to R&D spending v. peer group (chart)
Exh PFE5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh PFE6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh PFE7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh PFE8: Development stage portfolio by ICD-9 v. peer group (table)
Exh PFE9: Development stage portfolio by mechanism v. peer group (table)
Exh PFE10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh PFE11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh PFE12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh PFE13: Clinical development projects by source of innovations (table)
Regeneron
Exh REGN1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh REGN2: Regeneron potential / risk-adjusted launches, 2016-2021E (chart)
Exh REGN3: Regeneron Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh REGN4: Projected real economic returns to R&D spending v. peer group (chart)
Exh REGN5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh REGN6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh REGN7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh REGN8: Development stage portfolio by ICD-9 v. peer group (table)
Exh REGN9: Development stage portfolio by mechanism v. peer group (table)
Exh REGN10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh REGN11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh REGN12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh REGN13: Clinical development projects by source of innovations (table)
Roche
Exh ROCHE1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh ROCHE2: Roche potential / risk-adjusted launches, 2016-2021E (chart)
Exh ROCHE3: Roche Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh ROCHE4: Projected real economic returns to R&D spending v. peer group (chart)
Exh ROCHE5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh ROCHE6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh ROCHE7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh ROCHE8: Development stage portfolio by ICD-9 v. peer group (table)
Exh ROCHE9: Development stage portfolio by mechanism v. peer group (table)
Exh ROCHE10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh ROCHE11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh ROCHE12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh ROCHE13: Clinical development projects by source of innovations (table)
Shire
Exh SHPG1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh SHPG2: Shire potential / risk-adjusted launches, 2016-2021E (chart)
Exh SHPG3: Shire Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh SHPG4: Projected real economic returns to R&D spending v. peer group (chart)
Exh SHPG5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh SHPG6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh SHPG7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh SHPG8: Development stage portfolio by ICD9 v. peer group (table)
Exh SHPG9: Development stage portfolio by mechanism v. peer group (table)
Exh SHPG10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh SHPG11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh SHPG12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh SHPG13: Clinical development projects by source of innovations (table)
Sanofi
Exh SNY1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh SNY2: Sanofi potential / risk-adjusted launches, 2016-2021E (chart)
Exh SNY3: Sanofi Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh SNY4: Projected real economic returns to R&D spending v. peer group (chart)
Exh SNY5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh SNY6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh SNY7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh SNY8: Development stage portfolio by ICD-9 v. peer group (table)
Exh SNY9: Development stage portfolio by mechanism v. peer group (table)
Exh SNY10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh SNY11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh SNY12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh SNY13: Clinical development projects by source of innovations (table)
Vertex
Exh VRTX1: Share of trailing 10-yr R&D spend v/. Share of risk-adjusted new product launches, 2016 – 2023 (chart)
Exh VRTX2: Vertex potential / risk-adjusted launches, 2016-2021E (chart)
Exh VRTX3: Vertex Expected in-line and pipeline pharma sales ($M), 2014-2021E (chart)
Exh VRTX4: Projected real economic returns to R&D spending v. peer group (chart)
Exh VRTX5: Innovation yield per $1M real R&D spend (3yr MA) v. peer group (chart)
Exh VRTX6: Capitalized cost per quality adjusted patent ($M), 1993-2014 (table)
Exh VRTX7: Average relative quality of innovation (by grant year, 3yr MA) (chart)
Exh VRTX8: Development stage portfolio by ICD-9 v. peer group (table)
Exh VRTX9: Development stage portfolio by mechanism v. peer group (table)
Exh VRTX10: Share of company risk-adjusted launches by novelty & competitive status of MOA (chart)
Exh VRTX11: Development leadership in targeted MOA/ICD-9 pairs (table)
Exh VRTX12: Hidden Pipeline by therapeutic category v. peer group (table)
Exh VRTX13: Clinical development projects by source of innovations (table)
